Full-Time

Lead Consultant

Product Owner, AI & Microservice Platform

Posted on 5/8/2025

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Senior

Chennai, Tamil Nadu, India

Minimum of three days per week in the office, flexible work arrangements considered.

Category
Product Management
Product
Required Skills
Kubernetes
Microservices
Requirements
  • Relevant technical degree or equivalent.
  • Proven development/design experience in at least one infrastructure technical domain.
  • Detailed knowledge of Microservices Platform (Kubernetes/Containers/Serverless etc) and GPU-based AI platform and services based on On-Prem Private Cloud and how this can be applied to solve business problems.
  • Experience developing innovative solutions, blueprints, and standards for solution design.
  • Experience implementing and maintaining business solution architectures under any formal framework for their domain of architecture.
  • Experience developing and managing relationships with 3rd party suppliers.
  • Public and Private Cloud knowledge and awareness.
  • Proven ability to lead Proof of Concepts and Proof of Value activities through to Pilot stage where appropriate.
  • Experience developing Infrastructure as a Code, Platform automation skills.
Responsibilities
  • Drive innovation in the realm of Microservice Platform/High Performance Computing AI Platform/GPU-based platform support at Edge/Cloud/Hybrid Cloud and Technical Domains Enterprise Edge & Hybrid Cloud technologies.
  • Take ownership for and lead the development and implementation of technology roadmaps and strategies.
  • Authors and reviews solution blueprints for projects or solutions that address business/application/data/infrastructure requirements.
  • Works with Operations, Business Analysis, and Solution Engineering functions and supports functional & technical requirements management, including driving software/system selection processes.
  • Ensures that solution architectures and designs are highly resilient and address business, application, information, and infrastructure architectural requirements.
  • Accountable for architecting and designing comprehensive solutions that meet business requirements and are aligned to AstraZeneca’s Enterprise Architecture, in support of a given portfolio.
  • Partners with Enterprise Architects, Project Managers, Business Analysts, and Solution Engineers to create solutions aligned with AstraZeneca architecture standards and principles, demonstrating common solutions and services, and meeting financial targets (cost and benefits).
  • Accountable for solution evaluation and selection, buy vs. build decisions, and early-phase project estimates which contribute to the case.
  • Provides technical expertise support to project teams and conducts AZ architectural reviews throughout the project lifecycle.
  • Ensures compliance with existing EA guidelines and standards (e.g., AZ Architecture Engagement Process (ISPMM) and EA Software Standards).
  • Contributes to project and service teams in the development, implementation, and maintenance of standard architectural components.
  • Works with third-party suppliers as required and contributes to the creation of local or functional design documents.
  • Verifies technical development and delivery are in alignment with the Architecture Roadmap, Blueprint, and Information Services Strategy.
  • Documents all architecture analysis and design work.
  • Develops strong knowledge and expertise in at least one architecture domain.
  • Contributes to the development of the Architecture Capability within Information Services by documenting and sharing knowledge and standard methodologies with peer Architects and Engineers.
Desired Qualifications
  • Demonstrates initiative, strong customer orientation, and cross-cultural working.
  • Experience in developing/maturing an architectural practice.
  • Development knowledge and experience of scripting or programming languages.
  • Detailed knowledge of Microservices Platform (Kubernetes/Containers/Serverless etc).
  • GPU-based AI platform and services based on On-Prem Private Cloud.
  • Proven business insight.
  • Understanding of the pharmaceutical/healthcare industry and competitor activity on a particular architecture and Information Management.
  • Ability to work well in diverse, multinational teams with proven track record to influence others to achieve positive outcomes.
  • IT Sustainability goals.

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatment; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, involving rigorous clinical trials and regulatory approvals before reaching the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and forming strategic partnerships to enhance drug discovery. Their goal is to advance healthcare by creating effective treatments for serious diseases and collaborating with other organizations to improve their research capabilities.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • Opening of $300M CAR-T facility in Rockville boosts cell therapy capabilities.
  • Enhertu's success in DESTINY-Breast11 trial strengthens AstraZeneca's oncology portfolio.
  • AI-powered lung cancer detection tool enhances early diagnosis and treatment options.

What critics are saying

  • Discontinuation of CAPItello-280 trial impacts oncology pipeline and investor confidence.
  • Operational challenges may delay CAR-T facility's production scale-up.
  • AI-powered tools may face scrutiny over data privacy and accuracy.

What makes AstraZeneca unique

  • AstraZeneca's A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • The company invests heavily in R&D to create new drugs and therapies.
  • AstraZeneca's Open Innovation program accelerates drug discovery by sharing resources with scientists.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

MocoShow
May 9th, 2025
AstraZeneca Opens $300 Million CAR-T Manufacturing Facility in Rockville, Creating Over 150 Jobs

AstraZeneca opens $300 million CAR-T manufacturing facility in Rockville, creating over 150 jobs.

Cision
May 9th, 2025
Imfinzi Improved Dfs In Early Bladder Cancer

Imfinzi improved DFS in early bladder cancer

PharmiWeb
May 7th, 2025
Enhertu Followed By Thp Before Surgery Showed Statistically Significant And Clinically Meaningful Improvement In Pathologic Complete Response In Patients With High-Risk Her2-Positive Early-Stage Breast Cancer In Destiny-Breast11 Phase Iii Trial

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer. Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. The secondary endpoint of event-free survival (EFS) was not mature at the time of analysis; however, EFS data showed an early positive trend favouring Enhertu followed by THP compared to standard of care. The trial will continue to follow EFS

Cision
May 7th, 2025
Enhertu Improved Pcr In Early-Stage Breast Cancer

Enhertu improved pCR in early-stage breast cancer

Bethesda Magazine
May 6th, 2025
AstraZeneca opens cell therapy manufacturing site in Rockville

AstraZeneca announced in February 2024 that it was investing in the Rockville manufacturing facility.